Ablynx, a Sanofi company, is engaged in the development of NANOBODY® proteins, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. NANOBODY® proteins have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of NANOBODY®-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology.


The acquisition of Ablynx (June 2018) continues Sanofi’s commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules. Sanofi is committed to accelerating Ablynx’s NANOBODY® development programmes.


Ablynx was acquired
by Sanofi in June 2018

Unique and powerful
technology platform

>500 patents
granted and pending

~450 employees
20 nationalities